Nautilus Biotechnology (NASDAQ:NAUT) Research Coverage Started at Guggenheim
Guggenheim started coverage on shares of Nautilus Biotechnology (NASDAQ:NAUT – Free Report) in a research report released on Thursday, Marketbeat.com reports. The brokerage issued a buy rating and a $6.00 price objective on the stock. Separately, Jefferies Financial Group began coverage on shares of Nautilus Biotechnology in a research report on Monday, June 3rd. They […]
30 Jun 04:54 · The Cerbat Gem